Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1S | P09871 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 7/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | WHR1 | P49842 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063860 | 0.92 | LMNA (0.45) | LMNAALDH1A1MAPTALOX12SMN1; SMN2 | |
| SCHEMBL588907 | 0.88 | MEN1 (0.42) | LMNAMEN1KMT2ASCN9A | |
| Trifluoroacetic Acid SCHEMBL589972 | 0.88 | SLC2A1 (0.46) | C1SSLC2A1MAPTBRD4KMT2A | |
| SCHEMBL2912346 | 0.86 | ABL1 (0.41) | LMNAALDH1A1MAPTALOX12SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL591049 | 0.84 | JAK2 (0.41) | SLC2A1SCN9A | |
| SCHEMBL4075744 | 0.83 | LMNA (0.38) | LMNAALDH1A1MAPTALOX12SMN1; SMN2 | |
| SCHEMBL590220 | 0.83 | EGFR (0.41) | ALDH1A1MAPTSMN1; SMN2BRD4MEN1 | |
| SCHEMBL589895 | 0.81 | NPC1 (0.41) | LMNASLC2A1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL590116 | 0.81 | MAPT (0.43) | LMNAALDH1A1MAPTBRD4MEN1 | |
| Trifluoroacetic Acid SCHEMBL15400059 | 0.81 | MAPT (0.38) | LMNASLC2A1MAPTSMN1; SMN2WHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822474-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20140005154-A1 | 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-02 | — | — | US | disclosed |
| US-8604039-B2 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| EP-2010185-B1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2012-06-13 | — | — | EP | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| EP-1847543-A1 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | C1S 1094/4885LMNA 4706/4885SLC2A1 3521/4885 |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | DPYD, DHFR, TPMT | C1S 260/4885LMNA 4713/4885SLC2A1 1535/4885 |
| US-20140005154-A1 | 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases | DPYD, TYMS, TPMT | C1S 245/4885LMNA 4670/4885SLC2A1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.